Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005633 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
A Phase 1 study of Melanoma (Skin), sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00005633: Completed Phase 1 study of Melanoma (Skin), sponsored by Memorial Sloan Kettering Cancer Center.
NCT00005633 is a Phase 1 study of Melanoma (Skin) that has completed, run by Memorial Sloan Kettering Cancer Center. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005633, a Phase 1 study of Melanoma (Skin), has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma.
Conditions Studied
Interventions
- BIOLOGICAL OVA BiP peptide
- BIOLOGICAL gp209-2M antigen
- BIOLOGICAL recombinant 70-kD heat-shock protein
- BIOLOGICAL tyrosinase peptide
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-06 |
| Est. Completion | 2002-06 |
| Phase | Phase 1 |
What the finished NCT00005633 record still lists
NCT00005633 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 4 interventions - of which OVA BiP peptide is the first listed.
NCT00005633 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00005633 about?
NCT00005633 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma.
What is the current status of trial NCT00005633?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-06. Estimated completion is 2002-06.
What conditions does trial NCT00005633 study?
This clinical trial studies the following conditions: Melanoma (Skin).
What interventions are being tested in trial NCT00005633?
The interventions under investigation include: OVA BiP peptide (BIOLOGICAL), gp209-2M antigen (BIOLOGICAL), recombinant 70-kD heat-shock protein (BIOLOGICAL), tyrosinase peptide (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005633?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005633 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma (Skin)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
RECRUITING · Phase 1
-
Vaccine Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Biological Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia